Comparative preclinical assessment of relugolix tablets and relugolix intravenous injection.

At Day 12, highly significant reductions were observed in tumor width (*** p = 0.0009), length (** p = 0.0017), and volume (*** p = 0.0007) relative to control, whereas the tablet showed only modest effects on width (* p = 0.036) and volume (* p = 0.0379) and no significant effect on length ( p = 0.2243).

also in 132,142 other papers

Notably, the injectable formulation (10 mg kg −1 ) achieved highly significant tumor suppression ( p < 0.0003 on Day 15), whereas the oral tablet formulation (100 mg kg −1 ) failed to reach statistical significance despite a ten-fold higher administered dose.

also in 6,035 other papers